Skip to main content
. 2018 Mar 28;77(8):1107–1117. doi: 10.1136/annrheumdis-2018-213131

Table 5.

Proposed domains and items for outcome measures of juvenile idiopathic arthritis (JIA)-associated uveitis (from the Multinational Working Group in JIA-related uveitis)74

Domains Items
Grade of cells in anterior chamber Slit-lamp examination (according to SUN criteria)
Grade of flare in anterior chamber* Slit-lamp examination for routine clinical practice and prospective trials (according to SUN criteria)
Laser flare photometry for prospective trials
Number of visits with active uveitis Records of treating physician
  • Duration of activity over a minimum of four visits/year

Visual acuity (appropriate test for age) Best-corrected visual acuity
Thresholds: ≤20/50, ≤20/200 and no light perception
Estimate contribution of amblyopia, yes/no
Development of structural complications Synechiae, yes/no
  • Initial and additional

Ocular hypotony, yes/no (<5 mm Hg)
Ocular hypertension, yes/no (>21 mm Hg)
Glaucoma, yes/no
Cataract, yes/no
Band keratopathy in the central cornea, yes/no
Macular oedema by optical coherence tomography, yes/no
  • Funduscopy and optical coherence tomography for routine clinical practice (for macula and optic disc)

  • Funduscopy and optical coherence tomography for prospective trials

Epiretinal membrane formation, yes/no
  • Funduscopy for routine clinical practice

  • Funduscopy and optical coherence tomography for prospective trials

Quality of life Childhood Health Assessment Questionnaire
Child Health Questionnaire
Pediatric Quality of Life Inventory
Uveitis-specific quality of life instrument (not yet available for non-English speaking countries)
Overall uveitis-related disability Assessment by parents, visual analogue scale
Assessment by children, visual analogue scale
Assessment by treating ophthalmologist, visual analogue scale
Assessment by treating paediatric rheumatologist, visual analogue scale
Social outcome School/kindergarten absence
Anti-inflammatory medication* Reduction of corticosteroid dose—topical dose—systemic dose
Surgery* Yes/no
Biomarkers Research tools (not currently available

*Not an outcome measure, but should be documented.

SUN, Standardization of Uveitis Nomenclature.